Multiple sclerosis drug on fast track
Biogen Idec Inc., a Cambridge company known for its multiple sclerosis drugs, said the US Food and Drug Administration has granted it fast-track designation for a potential treatment of relapsing multiple sclerosis. (Full article: 108 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
